Efficacy Endpoint no New Cerebrovascular Adverse Events Within 1 Year |
Safety Endpoint no New Moderate or Serious Adverse Events Within 1 Year |
All-cause Mortality Events Within 1 Year |
Incident Ischemic Stroke Events Within 1 Year |
New Hemorrhagic Stroke Events Within 1 Year |
New Stent Thrombosis Events Within 1 Year |
New Symptomatic Stenosis Events Within 1 Year |
Occurrence of In-stent Stenosis 12th 1 Month Annual Angiographic Follow-up |
Degree of In-stent Stenosis as Measured by WASID Method at the 12th 1 Month Annual Angiographic Follow-up |
Target Aneurysm Embolization Rate at 121 Month Annual Angiographic Follow-up Raymond and OKM Classification |